Related Experiment Videos

TGF-betas and TGF-beta receptors in atherosclerosis

T A McCaffrey1

  • 1Weill Medical College of Cornell University, Department of Medicine, Division of Hematology/Oncology, New York, NY 10021, USA. tamccaf@med.cornell.edu

Insights

A defect in the transforming growth factor-beta (TGF-beta) system, specifically reduced Type II receptors, causes resistance to TGF-beta

Area of Science:

  • Cardiovascular Biology
  • Cellular Signaling
  • Wound Healing Research

Background:

  • Atherosclerosis and restenosis may stem from impaired endogenous inhibitory systems controlling wound repair.
  • The transforming growth factor-beta (TGF-beta) system is a key inhibitory pathway implicated in these conditions.
  • Human lesion-derived cells exhibit resistance to TGF-beta's normal inhibitory effects.

Purpose of the Study:

  • To investigate the role of the TGF-beta system defect in atherosclerosis and restenosis.
  • To characterize the specific alterations in TGF-beta receptors in human vascular lesions.
  • To determine the functional consequences of these receptor alterations on cell behavior.

Main Methods:

  • Analysis of TGF-beta signaling in cells derived from human vascular lesions versus normal vascular media.
  • Assessment of TGF-beta receptor expression (Type I, II, III) using membrane cross-linking and RT-PCR.
  • Functional studies involving transfection of TGF-beta Type II receptor into lesion cells.
  • Examination of receptor expression in human coronary and carotid artery lesions.

Main Results:

  • Lesion-derived cells are resistant to TGF-beta's antiproliferative and apoptotic effects, unlike normal cells.
  • A significant decrease in TGF-beta Type II receptors, and corresponding mRNA, was observed in lesion cells.
  • Normal cells express Types I, II, and III receptors, while lesion cells show reduced Type II receptor levels.
  • Restoration of Type II receptor in lesion cells partially restored TGF-beta responsiveness.
  • While some mutations exist, most resistance is linked to reduced Type II receptor levels, possibly due to transcriptional or processing defects.

Conclusions:

  • Defects in the TGF-beta Type II receptor are a critical factor in the pathogenesis of atherosclerosis and restenosis.
  • Reduced Type II receptor expression leads to uncontrolled cell growth and extracellular matrix overproduction in vascular lesions.
  • Targeting TGF-beta signaling or receptor restoration may offer therapeutic strategies for fibroproliferative vascular diseases.

Related Concept Videos